Erin Bastick
Erin Bastick is a PharmD Candidate 2016, Ohio Northern University, Ada, Ohio, and an inpatient intern at University Hospitals, Cleveland.
Are payers optimistic about biosimilars’ savings?
As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications.
Antidepressant drug pipeline: What to know
Antidepressant drug pipeline: What to know
There are promising developments in the pipeline for patients with treatment-resistant depression.
Asthma drug pipeline: Prevalence, costs to increase
Asthma drug pipeline: Prevalence, costs to increase
As asthma prevalence continues to rise in the adult and pediatric populations, U.S. healthcare spending on medications, especially branded inhalers, is expected to increase.
Empowered patients more likely to stick to diabetes treatments
Empowerment is an important factor to address everyday aspects of dealing with a chronic disease, including diabetes, according to a study that evaluated the effect of diabetes empowerment on medication adherence and self-care behaviors in adults with type 2 diabetes.
FDA approves rare liver disease drug
FDA recently granted accelerated approval for obeticholic acid (Ocaliva, Intercept Pharmaceuticals, Inc.) for the treatment of primary biliary cholangitis.
First 4-strain flu vaccine available
FDA recently approved the first 4-strain, cell culture-derived, inactivated seasonal flu vaccine available in the United States. Flucelvax Quadrivalent influenza vaccine (Seqirus) helps protect against the 2 influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season.
3 ways to improve diabetes med adherence
A systemic review highlights studies that improved medication adherence and patient outcomes using strategies that could be effective if employed in real-world healthcare settings.
Pharma company keeps pace with rise of diabetes
Novo Nordisk’s new diabetes drug production facility in Clayton, N.C., will ensure production capacity for these drugs in the United States for the decade ahead.
New treatment for kidney cancer gets OK
FDA has approved lenvatinib (Lenvima, Eisai Inc.) in combination with everolimus for the treatment of advanced renal cell carcinoma.
Opdivo snags two new cancer approvals
Nivolumab (Opdivo, Bristol-Myers Squibb) received two new approvals from FDA to treat two different cancers.

Poll

View Results